Summary of Amgen Conference Call Company Overview - **Company**: Amgen - **Key Participants**: Peter Griffith (CFO), Jasper van Grunsven (SVP of Rare Disease), Casey Capparelli (VP of Investor Relations) [8][1] Core Industry Insights - **Strong Portfolio Performance**: In 2025, Amgen reported strong momentum with 13 products delivering double-digit growth, 14 products exceeding $1 billion in annual sales, and 18 products achieving record performance [8][9] - **Key Growth Drivers**: The growth is supported by six key drivers: Repatha, Evenity, Tezspire, rare disease portfolio, innovative oncology, and biosimilars [8][9] - **Rare Disease Portfolio**: Generated $5 billion in sales in 2025, up 14% year-over-year, with significant contributions from UPLIZNA, which grew 73% due to new indications and geographic expansion [9][31] Financial Highlights - **Revenue and Earnings Growth**: Amgen experienced double-digit growth in both revenue and earnings per share in 2025 [8][9] - **Biosimilars Performance**: The biosimilars portfolio generated $3 billion in sales in 2025, growing 37% year-over-year, driven by strong uptake of Pavblu [11][20] - **Quarterly Expectations**: Anticipated seasonal headwinds in Q1 due to insurance cycles and historical sales patterns, particularly for Otezla and IMRALDI [14][15] Product-Specific Insights - **UPLIZNA**: Expected to continue strong growth with a focus on new indications and a competitive profile in the market [31][36] - **MariTide**: Positioned as a differentiated treatment for obesity and related conditions, with six global Phase III studies underway. Monthly dosing is expected to improve patient adherence [12][25][62] - **IMDELLTRA**: A bispecific T-cell engager for small cell lung cancer, rapidly becoming the standard of care with ongoing Phase III studies [10][19] Pipeline and Future Growth - **Pipeline Development**: 2026 is set to be a year of disciplined data generation across multiple Phase II and III programs, with a focus on long-term growth [12][20] - **Dazodalibep (DAS)**: Targeting Sjögren's disease, with a significant unmet need and promising Phase II data [50][51] Competitive Landscape - **Market Positioning**: Amgen is aware of competitive pressures, particularly in the obesity market from companies like Lilly and Novo, but believes its established commercial capabilities will provide a competitive edge [68][69] - **M&A Environment**: Amgen maintains a strong balance sheet and is open to M&A opportunities, focusing on innovation and integration capabilities [70][72] Additional Considerations - **Adherence and Patient Experience**: Emphasis on improving patient adherence through less frequent dosing regimens, which is crucial for chronic conditions [62][63] - **Commercial Strategy**: Amgen is strategizing on how to effectively position MariTide in a rapidly evolving market, considering both commercial and consumer segments [58][59]

Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics - **Participants**: - Stephen Mahoney - CEO - Shan Wu - CBO - Tony Casciano - CCO - **Conference**: TD Cowen's 46th Annual Healthcare Conference Key Points Industry and Market Insights - The Thyroid Eye Disease (TED) market in the U.S. has approximately 500,000 patients, with around 200,000 classified as moderate to severe and about 150,000 under physician care [doc id='22'] - Current treatment with TEPEZZA sees about 7,000 patients treated annually, indicating low single-digit market penetration [doc id='22'] - The company believes there is significant unmet need and opportunity to help more patients due to the burdensome treatment regimen of existing therapies [doc id='22'][doc id='23'] Product Development and Pipeline - **Veli (veligrotug)**: - Received Breakthrough Therapy designation and priority review from the FDA, with a PDUFA date set for June 30 [doc id='4'][doc id='11] - Phase 3 trials showed rapid onset of treatment effects, with significant improvements in diplopia (double vision) resolution [doc id='8'][doc id='9] - Treatment regimen involves 5 infusions at 10 mg/kg, compared to competitors' 8 infusions at 20 mg/kg, which is expected to appeal to patients and physicians [doc id='12][doc id='10] - **FcRn Programs**: - Two programs, VRDN-006 and VRDN-008, are in development, focusing on IgG suppression and albumin-sparing effects [doc id='5'][doc id='6] - Data from VRDN-008 is expected in the second half of the year, which will inform future development decisions [doc id='56] - **TSHR Program**: - A new program targeting the TSH receptor, which is believed to complement existing TED treatments and has potential applications in Graves' disease [doc id='58'][doc id='59] Commercial Strategy - The company plans to launch with a sales force of under 100 representatives, leveraging the existing market established by TEPEZZA [doc id='26'][doc id='27] - The strategy includes targeting all prescribers of TEPEZZA, which is estimated to be around 2,000 core prescribers [doc id='27] - The company aims to differentiate itself by offering a simpler and faster treatment option, which is expected to improve patient compliance and market penetration [doc id='12][doc id='23] Regulatory and Competitive Landscape - Consistent communication with the FDA has been maintained, which is viewed positively by the company [doc id='17'][doc id='18] - The competitive landscape is acknowledged, with a focus on differentiating Veli from existing therapies through its dosing regimen and efficacy [doc id='10][doc id='12] Future Outlook - The company is optimistic about the upcoming data readouts and believes that the clinical trial designs will effectively control for placebo effects [doc id='47][doc id='48] - There is a focus on expanding treatment options for TED and potentially addressing the chronic population, which may have different treatment urgencies [doc id='32][doc id='35] Additional Considerations - The company is exploring international opportunities, particularly in Europe and Japan, where there is a significant unmet need for TED treatments [doc id='36][doc id='40] - Pricing strategies in international markets remain a key consideration as the company prepares for potential launches [doc id='36] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's focus on innovation in the TED market and its commitment to addressing patient needs through differentiated therapies.

Core Viewpoint - Genmab A/S is highlighted as a high-growth international stock, with a strong buy rating and a price target of $39 following significant sales growth of DARZALEX in 2025 [1]. Group 1: Sales Performance - In 2025, worldwide net sales of DARZALEX reached $14.351 billion, an increase from $11.670 billion in 2024, representing a growth of approximately 22.9% [2]. - The US contributed over half of the sales, amounting to around $8.266 billion, while the rest of the world accounted for $6.085 billion [2]. Group 2: Royalty Revenue - Genmab does not sell DARZALEX directly but earns royalties from Johnson & Johnson, receiving $2.219 billion in total royalty revenue during the first nine months of 2025, up from $1.802 billion in the same period of 2024, marking a 23% year-over-year increase [4]. - Management had initially estimated full-year DARZALEX royalties to be between $2.3 billion and $2.4 billion, based on projected net sales of $13.7 billion to $14.1 billion, but actual sales exceeded expectations, indicating royalties will likely surpass $2.4 billion [5]. Group 3: Company Overview - Genmab A/S is a Denmark-based biotechnology company focused on developing antibody therapeutics for cancer treatment, co-developing drugs like DARZALEX, Kesimpta, and TEPEZZA, and earning royalties through licenses to partners such as Johnson & Johnson [6].

Core Insights - The article discusses the performance of international stocks and highlights the impact of the weakening US dollar and trade policies on global markets [2][3] Group 1: Market Trends - The weakness in the US dollar is identified as a major catalyst for the performance of global stocks, with the first half of 2025 being the worst for dollar weakness since the early 1970s [2] - Oversaturation in the "Magnificent Seven" has led investors to explore international markets, recognizing that technology growth is not limited to the US [2] - Trade and tariff wars have prompted international markets to adopt growth-friendly policies, resulting in increased trade deals and reduced regulatory barriers in regions like Europe, China, and India [3] Group 2: Investment Opportunities - The article presents a list of 10 high-growth international stocks, emphasizing the potential for attractive investment opportunities outside the US [4] - The methodology for selecting these stocks involved using stock screeners and hedge fund databases to identify companies with over 25% revenue growth over the past three years [6] Group 3: Company Highlights - Genmab A/S (NASDAQ:GMAB) reported a significant increase in net sales of DARZALEX, reaching $14.351 billion in 2025, up from $11.670 billion in 2024, with over half of the sales coming from the US [9][10] - Genmab's royalty revenue for the first nine months of 2025 was $2.219 billion, a 23% increase from $1.802 billion in the same period of 2024, attributed to higher sales of DARZALEX and Kesimpta [11] - BeOne Medicines AG (NASDAQ:ONC) received a Buy rating with a price target increase following the first-in-world approval of Sonrotoclax in China for treating difficult blood cancers, with a 52.4% overall response rate in MCL studies [14][15][16]

Core Insights - Genmab A/S (NASDAQ:GMAB) is recognized as a promising healthcare stock priced under $50, with significant sales figures reported for its product DARZALEX, totaling $14.351 billion in worldwide net trade sales for 2025 [1] - The company has received positive price target adjustments from analysts, with H.C. Wainwright setting a target of $39 and BofA adjusting it to $38.50, both maintaining a Buy rating, indicating confidence in Genmab's future performance [2] Company Overview - Genmab A/S is an international biotechnology company focused on developing human antibody therapeutics for cancer and other diseases, with a product pipeline that includes DARZALEX for multiple myeloma, TEPEZZA for thyroid eye disease, and Arzerra for chronic lymphocytic leukemia [3]

Core Insights - The article discusses the current state of healthcare stocks, particularly focusing on the impact of proposed changes to Medicare Advantage payments, which are expected to be minimal, leading to negative implications for major insurers [2][3]. Industry Overview - The healthcare sector has been described as "precarious" for investment over the past couple of years, with the recent Medicare Advantage proposal causing a shock to the system [3][4]. - Investors had anticipated a turnaround year, but the current outlook suggests a period where earnings may not grow as expected, indicating a challenging environment for healthcare investments [4]. Company Highlights - **Genmab A/S (NASDAQ:GMAB)**: - Reported worldwide net trade sales of DARZALEX at $14.351 billion for 2025, with $8.266 billion from the U.S. and $6.085 billion from the rest of the world [10]. - Analysts have adjusted price targets, with H.C. Wainwright setting it at $39 and BofA at $38.50, both maintaining a Buy rating, citing a "catalyst-rich" fiscal 2026 [11]. - The company focuses on developing human antibody therapeutics for cancer and other diseases, with a strong product pipeline [12]. - **Elanco Animal Health Incorporated (NYSE:ELAN)**: - Received multiple rating updates, with BofA raising the price target to $28 and UBS to $30, both maintaining Buy ratings due to stronger operational results [13][14]. - Piper Sandler upgraded the stock to Overweight, increasing the price target to $30, highlighting the company's progress in corporate channels [14]. - Elanco provides products and services for disease prevention and treatment in pets and farm animals, serving a diverse range of species [15].

Core Insights - Genmab A/S is highlighted as one of the most profitable biotech stocks to consider for investment, with a Buy rating maintained by H.C. Wainwright analyst Ram Selvaraju and a price target set at $40 [1][2]. Group 1: Clinical Developments - The company has shown promising clinical developments, particularly with rinatabart sesutecan (Rina-S) for endometrial cancer, which demonstrated notable response rates in patients regardless of OFRα expression levels [2][3]. - These results are particularly encouraging when compared to existing treatments, which exhibit lower overall response rates, such as the combination of ELAHERE and Keytruda [3]. Group 2: Product Pipeline - Genmab A/S is an international biotechnology company focused on developing human antibody therapeutics for cancer and other diseases [4]. - The company's product pipeline includes DARZALEX for multiple myeloma, TEPEZZA for thyroid eye disease, and Arzerra for chronic lymphocytic leukemia [4].

Financial Data and Key Metrics Changes - The company reported a 9% year-over-year revenue growth and a 13% volume growth in the second quarter [5] - Non-GAAP earnings per share grew by 21% year-over-year [5] Business Line Data and Key Metrics Changes - In general medicine, Repatha achieved $689 million in sales, growing at 31% year-over-year, while Evenity reached $518 million in sales with a growth of 32% year-over-year [8] - The rare disease segment is now annualizing at over $5 billion, with significant growth from Oplisna and a successful launch in IgG4 related disease [9][10] - The oncology portfolio saw BLINCYTO grow by 45% year-over-year, and IMDELTRA grew at 65% quarter-over-quarter, generating $134 million in sales [13] - The inflammation segment, particularly TestFire, grew by 46% year-over-year in severe uncontrolled asthma [14] Market Data and Key Metrics Changes - The company is expanding its presence in Japan with the successful launch of TEPEZZA and is having ongoing conversations with payers in Europe [70] Company Strategy and Development Direction - The company emphasizes a commitment to innovation, execution excellence, and disciplined capital allocation, with an increased R&D spend guidance of over 20% for the year [15][24] - The focus is on expanding the pipeline, particularly in obesity and cardiometabolic risk management, with multiple Phase III studies ongoing [18][19][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ability to serve more patients and address unmet medical needs, highlighting the importance of both inline products and pipeline innovations [72] - The company is well-positioned for long-term growth, with a strong platform and breadth across therapeutic areas [72] Other Important Information - The company has largely completed deleveraging from the Horizon transaction and is on track to return to an efficient capital structure by the end of the year [16] Q&A Session Summary Question: Discussion on Meratide and its safety profile - Management discussed the Phase II study's focus on dose escalation and the pharmacokinetic characteristics of Meratide, which allow for smooth titration to target doses [26][27] Question: Broader program for Meratide - Management highlighted the broad maritime program, including studies in cardiovascular disease and chronic weight management, indicating significant potential in these areas [33][32] Question: Opportunities with Repatha and Vesalius CV trial - Management noted that the Vesalius study will add to the evidence supporting Repatha's use in primary prevention, which is crucial for payer acceptance [42] Question: Positioning of Aplizna in the market - Management emphasized Aplizna's stable efficacy, steroid tapering capability, and attractive dosing schedule as key differentiators in the market [66][67] Question: Progress in geographical expansion post-Horizon deal - Management confirmed successful sales of TEPEZZA in Japan and ongoing discussions with European payers, indicating positive progress in geographical expansion [70]

Financial Data and Key Metrics Changes - The company reported a 9% year-over-year revenue growth and a 21% growth in non-GAAP earnings per share [5][15] - Volume growth was reported at 13% year-over-year [5] Business Line Data and Key Metrics Changes - In general medicine, Repatha achieved $689 million in sales, growing 31% year-over-year, while Evenity reached $518 million, growing 32% year-over-year [6] - Rare disease segment is now annualizing at over $5 billion, with significant growth from Oplisna and TEPEZZA [7][10] - Oncology portfolio saw BLINCYTO grow 45% year-over-year, and IMDELTRA grew 65% quarter-over-quarter, generating $134 million in sales [11] - Inflammation products, particularly TestFire, grew 46% year-over-year in severe uncontrolled asthma [13] Market Data and Key Metrics Changes - The company is expanding its presence in Japan with TEPEZZA and has received approval in Europe, indicating a focus on geographical expansion [71] - The rare disease market is expected to grow, with the company leveraging its manufacturing capabilities to enhance market access [70] Company Strategy and Development Direction - The company emphasizes a commitment to innovation across its therapeutic areas, focusing on execution excellence and disciplined capital allocation [24] - Increased R&D spending guidance to over 20% this year reflects the company's prioritization of innovation [14] - The company is exploring business development opportunities, including acquisitions and partnerships, to expand its portfolio [37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to deliver growth and innovation, citing a strong pipeline and the potential for new product launches [24][74] - The focus remains on addressing unmet medical needs and expanding access to therapies for patients [73] Other Important Information - The company has largely completed deleveraging from the Horizon transaction and aims to return to an efficient capital structure by year-end [15] - The pipeline includes multiple Phase III studies across various therapeutic areas, indicating a robust development strategy [16][19] Q&A Session Summary Question: Discussion on Meratide's safety and dosing - Management discussed the ongoing Phase II study addressing dose escalation and the potential for lower doses to maintain tolerability [26][27] Question: Broader program for Meratide - The company is exploring additional indications for Meratide, including cardiovascular disease and obstructive sleep apnea, based on encouraging Phase II data [33][32] Question: Repatha's opportunity in primary prevention - Management highlighted the Vesalius study's potential to reinforce the value of Repatha in primary care settings [40][41] Question: Olpasiran's positioning in cardiovascular disease - The company believes Olpasiran could achieve significant reductions in Lp(a) levels, differentiating it from competitors [47][50] Question: TESPIRE's potential in COPD - Management expressed confidence in TESPIRE's effectiveness in COPD based on its mechanism of action and previous data in severe asthma [56][58] Question: Bimertuzumab's regulatory filing approach - The decision on regulatory filing will depend on the totality of evidence from ongoing studies [63] Question: Aplizna's market positioning - Aplizna is positioned strongly in the market due to its dosing schedule and efficacy in treating IgG4 related disease and generalized myasthenia gravis [66][68] Question: Progress in geographical expansion post-Horizon deal - The company is successfully launching products in new markets, including Japan, and is optimistic about future growth in rare diseases [71][70]

Financial Data and Key Metrics Changes - Revenues grew by 9% year over year, with volume increasing by 13% [4][10] - Non-GAAP operating expenses rose by 8%, with non-GAAP R&D growth of 18% year over year [33] - Free cash flow generated in the second quarter was $1.9 billion, reflecting operational momentum [33] Business Line Data and Key Metrics Changes - General Medicine sales increased, with Repatha delivering $696 million, up 31% year over year [10][11] - EVENITY sales increased by 32% year over year to $518 million, with significant growth in the U.S. and Japan [11][12] - Rare disease portfolio grew by 19% year over year, delivering nearly $1.4 billion in sales [14] - Oncology portfolio generated $2.2 billion in sales, growing 14% year over year [18] - Biosimilars portfolio sales grew by 40% year over year to $661 million [20] Market Data and Key Metrics Changes - The U.S. market saw continued demand growth across cardiology and primary care [11] - Inflammation treatments showed strong adoption, with TestBio sales up 46% year over year [17] - The biosimilars market is evolving, with Amgen's portfolio generating nearly $12 billion in sales since 2018 [20][86] Company Strategy and Development Direction - The company is focused on innovation and expanding its pipeline, particularly in obesity, rare diseases, and oncology [6][8] - AI is seen as a key driver for enhancing innovation across the company [7][34] - The company aims to improve patient access and affordability while maintaining a commitment to innovation [5][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver innovation and growth in the long term [9][36] - The company anticipates total revenues for 2025 to be in the range of $35 billion to $36 billion [35] - Management acknowledged the need for reform in the U.S. healthcare system to improve medicine affordability [45][46] Other Important Information - The company is investing heavily in its late-stage pipeline, with a focus on Meritide and other key programs [34][36] - Capital expenditures for 2025 are expected to be $2.3 billion to expand network capacity [34] Q&A Session Summary Question: Granularity on Meritide data in Q4 - Management indicated that more data will be shared in due course regarding the phase two type two diabetes study and chronic weight management studies [41][42] Question: Thoughts on drug pricing reforms - Management emphasized the need for reform in the U.S. healthcare system and expressed a willingness to work with the administration to achieve objectives [44][46] Question: Appetite for M&A in rare diseases - Management remains interested in growing the rare disease business both organically and through potential acquisitions [49][50] Question: Design considerations for Meritide CVOT study - Management acknowledged the interest in the recent data from competitors and indicated that they are closely monitoring the situation [65][66] Question: Timeline for filing approval for bimetuzumab - Management has not disclosed the regulatory strategy yet but is excited about the positive results and their implications for patient treatment [70][71] Question: Confidence in the TestBiR COPD program - Management expressed strong confidence in the mechanism and the responder population for the TestBiR program [106][107] Question: Future of obesity treatments - Management is exploring opportunities to augment their offerings in obesity, including the potential for oral small molecules [111]